<div id="readability-page-1"><ul><li>FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026</li></ul><p>Eli Lilly and Company, Pfizer, Novo Nordisk A/S, Ironwood Pharmaceuticals,  and AbbVie are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell prescription drugs and therapies. For investors, their value is driven largely by drug pipelines, clinical-trial results, regulatory approvals, patent protection, and reimbursement dynamics, making them potentially high-growth but also higher-risk and event-sensitive. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><h2>Eli Lilly and Company (LLY)</h2><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><ul><li>Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake</li></ul><p>Read Our Latest Research Report on LLY</p><h2>Pfizer (PFE)</h2><p>Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p><ul><li>Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026</li></ul><p>Read Our Latest Research Report on PFE</p><h2>Novo Nordisk A/S (NVO)</h2><p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p><p>Read Our Latest Research Report on NVO</p><h2>Ironwood Pharmaceuticals (IRWD)</h2><p>Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.</p><p>Read Our Latest Research Report on IRWD</p><h2>AbbVie (ABBV)</h2><p>AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p><p>Read Our Latest Research Report on ABBV</p><h2>Featured Stories</h2><ul><li>MarketBeat's Top Five Stocks to Own in January 2026</li><li>3 Cybersecurity Stocks to Watch in 2026 as Identity and Endpoint Converge</li><li>Hi Ho Silver Away! Silver Breaks $80 as Poor Man's Gold Explodes</li><li>Duke Energy’s Nuclear Bet Signals the AI Power Shift</li><li>Actions Speak Louder: Why This CEO Kept Buying His Own Stock</li><li>Find the Next NVIDIA With This Semiconductor ETF</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IRWD

ABBV

<p>Eli Lilly, Pfizer, Novo Nordisk, Ironwood Pharmaceuticals, and AbbVie are highlighted as promising pharmaceutical stocks to watch, according to MarketBeat. These companies are involved in the research, development, and sale of prescription drugs, with their stock values influenced by drug pipelines and regulatory approvals. Notably, Novo Nordisk's Wegovy pill has received FDA approval, marking a significant development. Investors are advised to consider these stocks due to their high trading volumes and potential for growth, despite inherent risks.</p>

Promising Pharmaceutical Stocks To Consider - January 2nd